Regemat

Regemat 3D was founded in 2015 and has been developing a modular 3D bioprinting platform over the past seven years. The system is compatible with Fused Filament Fabrication (FFF), Injection Pore Filling (IPF), and Injection Volume Filling (IVF) print heads, enabling users to apply various technologies and materials tailored to specific laboratory needs. Currently, the company's product portfolio includes software, bioreactors, materials, accessories, as well as the R&D BIO V1 and REG4LIFE 3D bioprinters. Regemat3D believes that personalized functional tissues created through bioprinting can treat patients, cure diseases, and ultimately improve people’s quality of life.